There was agreement that denosumab is an effective treatment for rare, disabling RANKL-mediated disorders in children, such as giant cell-rich bone tumors and fibrous dysplasia (FD), and potential treatment for others, such as juvenile Paget disease (JPD), for which other effective treatments are lacking. The gene discussed is TNFSF11; the disease is juvenile Paget disease.